Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Time to abandon single-site irradiation for inducing abscopal effects
Eric D. Brooks, Joe Y. Chang
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 123-135
Closed Access | Times Cited: 276

Showing 1-25 of 276 citing articles:

Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zengfu Zhang, Xu Liu, Dawei Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 359
Applications of single-cell sequencing in cancer research: progress and perspectives
Yalan Lei, Rong Tang, Jin Xu, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 356
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Sean McBride, Eric J. Sherman, C. Jillian Tsai, et al.
Journal of Clinical Oncology (2020) Vol. 39, Iss. 1, pp. 30-37
Open Access | Times Cited: 330
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Claire Lhuillier, Nils-Petter Rudqvist, Olivier Elemento, et al.
Genome Medicine (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 222
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
James W. Welsh, Hari Menon, Dawei Chen, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001001-e001001
Open Access | Times Cited: 216
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea, Fabrice André, Aurélien Marabelle, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 874-899
Open Access | Times Cited: 188
Carbon Ion Radiobiology
Walter Tinganelli, Marco Durante
Cancers (2020) Vol. 12, Iss. 10, pp. 3022-3022
Open Access | Times Cited: 173
Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite”
Ainhoa Arina, Stanley I. Gutiontov, Ralph R. Weichselbaum
Clinical Cancer Research (2020) Vol. 26, Iss. 12, pp. 2777-2782
Open Access | Times Cited: 167
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer
Chad Tang, Alexander D. Sherry, Cara Haymaker, et al.
JAMA Oncology (2023) Vol. 9, Iss. 6, pp. 825-825
Open Access | Times Cited: 98
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
Chi‐Leung Chiang, K.W. Chiu, Kenneth Sik Kwan Chan, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 169-178
Closed Access | Times Cited: 75
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Mathieu Spaas, Nora Sundahl, Vibeke Krüse, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1205-1205
Open Access | Times Cited: 47
Radiotherapy–immunotherapy combinations – perspectives and challenges
Michele Mondini, Antonin Lévy, Lydia Meziani, et al.
Molecular Oncology (2020) Vol. 14, Iss. 7, pp. 1529-1537
Open Access | Times Cited: 130
Integration of radiotherapy and immunotherapy for treatment of oligometastases
Sean P. Pitroda, Steven J. Chmura, Ralph R. Weichselbaum
The Lancet Oncology (2019) Vol. 20, Iss. 8, pp. e434-e442
Closed Access | Times Cited: 129
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
Yu Chen, Min Gao, Zhaoqin Huang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 125
Radiation-induced bystander and abscopal effects: important lessons from preclinical models
Élisabeth Daguenet, Safa Louati, Anne‐Sophie Wozny, et al.
British Journal of Cancer (2020) Vol. 123, Iss. 3, pp. 339-348
Open Access | Times Cited: 108
Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials
Dawei Chen, Vivek Verma, Roshal R. Patel, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 108, Iss. 1, pp. 196-203
Closed Access | Times Cited: 106
Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer
Limei Yin, Jianxin Xue, Rui Li, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 108, Iss. 1, pp. 212-224
Closed Access | Times Cited: 106
Radioimmunotherapy for the treatment of head and neck cancer
Sana D. Karam, David Raben
The Lancet Oncology (2019) Vol. 20, Iss. 8, pp. e404-e416
Closed Access | Times Cited: 93
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
Amy J. Wisdom, Yvonne M. Mowery, Cierra S. Hong, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 87
Radiotherapy and the immune system: More than just immune suppression
Michael Rückert, Ann-Sophie Flohr, Markus Hecht, et al.
Stem Cells (2021) Vol. 39, Iss. 9, pp. 1155-1165
Open Access | Times Cited: 87
Tumor-Targeted Nanomedicine for Immunotherapy
Horacio Cabral, Hiroaki Kinoh, Kazunori Kataoka
Accounts of Chemical Research (2020) Vol. 53, Iss. 12, pp. 2765-2776
Closed Access | Times Cited: 86
Cerenkov Luminescence-Induced NO Release from 32P-Labeled ZnFe(CN)5NO Nanosheets to Enhance Radioisotope-Immunotherapy
Longlong Tian, Yaxing Wang, Lele Sun, et al.
Matter (2019) Vol. 1, Iss. 4, pp. 1061-1076
Open Access | Times Cited: 84
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
Cristina Masini, C. Iotti, Ugo De Giorgi, et al.
European Urology (2021) Vol. 81, Iss. 3, pp. 274-282
Closed Access | Times Cited: 81
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer
Dawei Chen, Hampartsoum B. Barsoumian, Liangpeng Yang, et al.
Cancer Immunology Research (2020) Vol. 8, Iss. 7, pp. 883-894
Open Access | Times Cited: 73
Zoledronic Acid–Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment
Zhusheng Huang, Dan Yao, Qingsong Ye, et al.
ACS Nano (2021) Vol. 15, Iss. 5, pp. 8450-8465
Closed Access | Times Cited: 72
Page 1 - Next Page

Scroll to top